Leukemia
PHASE II, OPEN-LABEL, PROSPECTIVE SINGLE-ARM, MULTI-CENTER CLINICAL TRIAL TO EVALUATE IF ADDING VENETOCLAX TO PATIENTS ON COVALENT BTKI FOR 1L CLL CAN ACHIEVE DEEP DURABLE REMISSIONS (BY uMRD 10-4) TO ALLOW OFF-TREATMENT PERIOD (ML45219)
- Details
ClinicalTrials.gov ID:
NCT06524375
Diagnosis Type:
NA
USOR Number:
- Address
,
P: